Twist Bioscience touts positive preclinical data for SARS-CoV-2 antibodies

By The Science Advisory Board staff writers

Twist Bioscience has touted preclinical results for three of its proprietary antibodies against the novel coronavirus S1 subunit protein.

The data demonstrate that TB202-3 and TB202-63 protected against weight loss, an indicator of disease severity, starting at 1 mg/kg in a hamster challenge model, and TB181-36 protected against weight loss at 5 mg/kg and 10 mg/kg, according to Twist. In comparison, control animals lost 12% of their body weight.

TB202-63 and TB202-3 are single-domain VHH (nanobody) candidates found through synthetic antibody discovery libraries for candidates that could bind to the SARS-CoV-2 S1 receptor. TB181-36 is an immunoglobulin G (IgG) antibody based on those found in individuals recovered from COVID-19.

The studies were conducted in collaboration with the U.S. Army Medical Research Institute of Infectious Diseases and Vanderbilt University Medical Center. Twist plans to explore opportunities to further develop all three antibodies internally or with partners.

Copyright © 2020

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking